R-20 20 mg (Tablet (Enteric Coated))
Unit Price: ৳ 5.00 (140's pack: ৳ 700.00)
Medicine Details
| Category | Details |
|---|---|
| Generic | Rabeprazole sodium |
| Company | Asiatic laboratories ltd |
Indications
- Treatment of active duodenal ulcer
- Treatment of active benign gastric ulcer
- Symptomatic erosive or ulcerative gastro-esophageal reflux disease (GERD)
- Long-term management of gastro-esophageal reflux disease (GERD maintenance)
- Symptomatic treatment of moderate to very severe gastro-esophageal reflux disease (symptomatic GERD)
- Treatment of Zollinger-Ellison Syndrome
- Eradication of Helicobacter pylori in patients with peptic ulcer disease
Pharmacology
- Suppression of gastric acid secretion
- Inhibition of gastric H+/K+-ATPase
Dosage
- Recommended dose for active duodenal ulcer and active benign gastric ulcer is 20 mg once daily in the morning
- Recommended oral dose for erosive or ulcerative gastro-esophageal reflux disease (GERD) is 20 mg once daily for four to eight weeks
- For long-term management of GERD, a maintenance dose of rabeprazole sodium 20 mg or 10 mg once daily can be used
- 10 mg once daily for symptomatic treatment of moderate to very severe gastro-esophageal reflux disease (symptomatic GERD)
- Treatment of GERD in pediatric patients 1 to 11 years of age: 5 mg or 10 mg once daily depending on weight
- Recommended starting dose for Zollinger-Ellison Syndrome is 60 mg once a day, titrated upwards as necessary
- Combination therapy for H. pylori eradication: rabeprazole sodium 20 mg twice daily
Administration
- Tablets should be taken in the morning, before eating
- Tablets should not be chewed or crushed, but swallowed whole
Interaction
- Potential interaction with pH-dependent compounds
- Co-administration with ketoconazole or itraconazole may decrease antifungal plasma levels
- No interaction with liquid antacids observed
- Not recommended to be co-administered with atazanavir
Contraindications
- Hypersensitivity to the active substance or excipients
- Contraindicated in pregnancy and during breastfeeding
Side Effects
- Headache
- Diarrhea
- Abdominal pain
- Vomiting
- Constipation
- Dry mouth
- Changes in appetite
- Muscle pain
- Drowsiness
- Dizziness
Pregnancy & Lactation
- US FDA pregnancy category 'C'
- No adequate and well-controlled studies in pregnant women
- Likely excretion in human milk
Precautions & Warnings
- Gastric or esophageal malignancy should be excluded prior to treatment
- Regular surveillance for long-term treatment patients
- Possible increased risk of hip, wrist, and spine fractures with long-term use, especially in the elderly
- Risk of cross-hypersensitivity reactions with other proton pump inhibitors or substituted benzimidazoles
- Post marketing reports of blood dyscrasias and hepatic enzyme abnormalities
- Monitoring of magnesium levels for patients on prolonged treatment
Use in Special Populations
- No dosage adjustment necessary for renal or hepatic impairment
- Not recommended for use in children due to lack of data
Overdose Effects
- Maximum established exposure not exceeding 60 mg twice daily or 160 mg once daily
- Effects generally minimal, reversible without further medical intervention
Therapeutic Class
- Proton Pump Inhibitor
Storage Conditions
- Keep below 30°C temperature, away from light and moisture
- Keep out of the reach of children
Chemical Structure
- Molecular Formula: C18H21N3O3S
Common Questions
- R-20 20 mg Tablet is a proton pump inhibitor (PPI) that suppresses gastric acid secretion
- Used to treat duodenal ulcer, gastric ulcer, GERD, Zollinger-Ellison Syndrome, Helicobacter pylori eradication
- Common side effects include diarrhea, constipation, nausea, vomiting, headache, dizziness, rash, dry mouth
- R-20 20 mg Tablet should be taken with food, and the usual dose is one tablet once a day
- Not recommended for use during pregnancy or breastfeeding
- Symptomatic and general supportive measures should be utilized in case of overdose